Joy Melnikow, M.D., M.P.H.
 Joy A. Melnikow, M.D., M.P.H. Associate Director, Center for Healthcare Policy and Research Professor, Family and Community Medicine Address UC Davis Medical Center 4860 Y Street, Ste 2300 Sacramento, California 95817 Phone (916) 734-3160 e-mail jamelnikow@ucdavis.edu Research Interests Management of low grade abnormalities of pap smears; effects of decision and cost-effectiveness analysis on evaluation of contrasting management strategies Responsibilities include teaching and supervision of residents and medical students with a particular focus on problem-based learning, evidence-based medicine and maternal child health, as well as obstetrics and inpatient attending; mentoring and supervision of research fellows; mentoring junior faculty, providing direct outpatient and obstetric care; obtaining grant funding for, and conducting research projects, serving on the Executive Committee of the Center for Healthcare Policy and Research and the UC Davis Medical Center Cancer Center. Current research interests include women’s health, patient preferences and decision-making, preventive services, cancer prevention and early detection, underserved populations and cost-effectiveness analysis in women’s health care.  |
Recent Publications
Do personal and societal preferences differ by socio-demographic group?
Franks P, Lubetkin EI, Melnikow J.
Health Econ, 2007 Mar;16(3):319-25.
Chemoprevention: drug pricing and mortality: the case of tamoxifen
Melnikow J, Kuenneth C, Helms LJ, Barnato A, Kuppermann M, Birch S, Nuovo J.
Cancer, 2006 Sep 1;107(5):950-8.
Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Kulasingam SL, Myers ER, Lawson HW, McConnell KJ, Kerlikowske K, Melnikow J, Washington AE, Sawaya GF.Obstet Gynecol. 2006 Feb;107(2 Pt 1):321-8.
Human papillomavirus triage of atypical squamous cells of undetermined significance: cost-effective, but at what cost?
Melnikow J, Birch S .
J Natl Cancer Inst. 2006 Jan 18;98(2):82-3.
Recruitment strategies for minority participation: challenges and cost lessons from the POWER interview.
Keyzer JF, Melnikow J, Kuppermann M, Birch S, Kuenneth C, Nuovo J, Azari R, Oto-Kent D, Rooney M.
Ethn Dis. 2005 Summer;15(3):395-406.
"I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.
Paterniti DA, Melnikow J, Nuovo J, Henderson S, DeGregorio M, Kuppermann M, Nease R.
Ethn Dis. 2005 Summer;15(3):365-72.
Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S.
Cancer. 2005 May 15;103(10):1996-2005.
Medical adherence research: time for a change in direction?
Kravitz RL, Melnikow J.
Med Care. 2004 Mar;42(3):197-9. Review.
Networked for change? Identifying obstetric opinion leaders and assessing their opinions on cesarean delivery
Kravitz RL, Melnikow J, Romano PS, Franz CE, Gilbert W, Zach A, Paterniti DA, Krackardt D.
Social Science and Medicine, 2003;57:2423-2434.
Conservative versus aggressive follow up of mildly abnormal Pap smears: Testing for process utility
Birch S, Melnikow J, Kuppermann M.
Health Economics 2003;7(2):3-8.
Management of the low-grade abnormal Pap smear: What are women’s preferences?
Melnikow J, Kuppermann M, Birch S, Chan BK, Nuovo J.
J Fam Pract 2002;51(10):849-
Reporting number needed to treat and absolute risk reduction in randomized controlled trials
Nuovo J, Melnikow J, Chang D.
JAMA 2002;282(21):2813-14.